HGH vs CJC-1295 + Ipamorelin vs Tesamorelin: Evidence, Price, and Buyer Guide

Short Answer: Choose the GH Lane That Matches the Goal

HGH, CJC-1295 plus ipamorelin, and tesamorelin all engage the growth hormone axis, but they are three different purchases.

Somatropin supplies recombinant human growth hormone directly. It is the clearest replacement choice for clinician-confirmed adult growth hormone deficiency.

CJC-1295 plus ipamorelin stimulates your own GH release through two complementary signals. CJC-1295 acts through the GHRH receptor, while ipamorelin activates the ghrelin receptor. For research buyers, this lane offers broad vendor choice, blends, separate vials, and aggressive price competition.

Tesamorelin is also a GHRH analog, but it has the strongest compound-specific human outcome evidence in this comparison: approximately 18% visceral-fat reduction in adults with HIV-associated central fat accumulation.

The buying shortcut is simple. Match the mechanism and evidence to the goal, compare live prices at /prices, then verify lot proof at /vendors. Do not compare HGH international units with peptide milligrams as if they were equivalent.

What Each Product Actually Does

Somatropin bypasses pituitary release and directly replaces endogenous GH. The FDA label covers adults with confirmed growth hormone deficiency.

CJC-1295 is a GHRH analog. The DAC form binds albumin for prolonged exposure. The product often sold as CJC-1295 without DAC is short-acting Mod GRF 1-29. Confirm the exact form before buying because the names are frequently blurred.

Ipamorelin is a selective ghrelin-receptor agonist and GH secretagogue. Human pharmacology found a GH-release episode peaking at about 0.67 hours, then declining toward negligible concentrations.

Tesamorelin is a stabilized 44-amino-acid GHRH analog. It stimulates pituitary signaling, but it is not somatropin or CJC-1295.

Evidence Comparison: Replacement and Hormone Signals

The Endocrine Society says GH therapy can improve body composition, exercise capacity, skeletal integrity, and quality of life in adults with confirmed growth hormone deficiency. People with more severe deficiency generally have the greatest expected benefit.

CJC-1295 has clear human biomarker evidence. In healthy adults, a randomized study found sustained, dose-dependent increases in GH and IGF-1. A related study found higher trough and mean GH, increased IGF-1, and preserved GH pulsatility.

Those findings establish hormone signaling, not guaranteed muscle gain, fat loss, sleep improvement, or recovery. Long-term outcome trials of the CJC-1295 plus ipamorelin stack are lacking.

Ipamorelin also clearly triggers GH release in short human pharmacology studies. Its largest published clinical trial, however, tested postoperative ileus rather than physique or recovery outcomes. Among 114 patients, time to first tolerated meal was 25.3 hours with ipamorelin versus 32.6 hours with placebo. The result was not statistically significant at p=0.15.

That evidence hierarchy matters at checkout. Somatropin has an established replacement role for confirmed deficiency. CJC-1295 and ipamorelin have human evidence for GH-axis signaling, but broader benefit claims run ahead of the trials.

The compounds also share practical comparison factors. GH-axis products can affect fluid retention, joints, glucose tolerance, and IGF-1. Somatropin and tesamorelin labels include active-malignancy restrictions. These details help distinguish the products, but they do not change the buying workflow: choose the right mechanism, then demand a well-documented lot.

Tesamorelin Has the Strongest Specific Peptide Outcome Data

Tesamorelin stands apart because its evidence includes a measured clinical body-composition outcome, not only hormone levels.

A randomized placebo-controlled trial with a safety extension reported approximately 18% visceral-fat reduction in adults with HIV-associated central fat accumulation. Pooled phase 3 evidence is commonly summarized as roughly 15% to 18% at 26 weeks.

That makes tesamorelin the strongest peptide choice here when the buying priority is human visceral-fat evidence. The population matters, though. This was HIV-associated lipodystrophy, not ordinary weight loss, and the result should not be promised to the general population.

There is no head-to-head trial comparing HGH, CJC-1295 plus ipamorelin, and tesamorelin. There is also no basis for claiming that CJC-1295 plus ipamorelin reproduces HGH replacement outcomes.

The most useful evidence ranking is:

1. Prescription somatropin has the clearest role for confirmed growth hormone deficiency.
2. Tesamorelin has the best specific human outcome data among the compared peptides.
3. CJC-1295 has sustained GH and IGF-1 biomarker data with preserved pulsatility.
4. Ipamorelin has short-term human GH-release evidence, but its 114-patient clinical trial missed statistical significance on the primary outcome.

For a deeper compound comparison, read /blog/cjc-1295-ipamorelin-vs-tesamorelin-buyer-guide and /blog/tesamorelin-buyer-guide. The individual education pages at /peptides/cjc-1295, /peptides/ipamorelin, and /peptides/tesamorelin make it easier to compare mechanism before looking at price.

Current Prices: Singles and Blends

PeptidePub's August 4, 2026 checkpoint shows how heavily discounts can reorder the market. Prices exclude shipping.

Ipamorelin: - AMP 10 mg: $44 list, $39.60 after 10% PEPTIDEPUB, or $3.96/mg.

CJC-1295: - Peptide Society 10 mg: $49.99 list, $39.99 after 20%, about $4.00/mg. - Valor 10 mg: $48.99 list, $44.09 after 10%, about $4.41/mg.

CJC-1295 plus ipamorelin blends: - Ascension 20 mg: $118 list, $59 after 50%, or $2.95 per combined mg. - AMP 10 mg: $53 list, $47.70 after 10%, or $4.77 per combined mg.

Tesamorelin: - Ascension 5 mg: $50 list, $25 after 50%, or $5.00/mg. - Valor 32 mg: $169.99 list, $152.99 after 10%, about $4.78/mg.

These are research-product snapshots, not prescription somatropin or branded EGRIFTA prices. HGH may be labeled in international units and milligrams, so forcing it into the same price-per-mg ranking would mislead buyers.

Use /prices/cjc-1295, /prices/ipamorelin, /prices/cjc-1295-ipamorelin-blend, and /prices/tesamorelin for current inventory and codes. /tools/cost-per-dose helps normalize after-code value. Compare the delivered order because prices, inventory, discounts, and shipping change.

Blend vs Separate Vials

A premixed CJC-1295 plus ipamorelin vial can be simpler and cheaper. Ascension's discounted 20 mg blend at $2.95 per combined mg is the lowest checkpoint here.

Combined milligrams can hide details. A 10 mg blend might contain 5 mg plus 5 mg, but never assume that ratio. The label and lot evidence should state each component amount.

Separate vials make identity, quantity, and price easier to audit. They also distinguish CJC-1295 DAC from no-DAC and preserve buying flexibility.

Require a matching batch, named independent lab, report date, verifiable ID, LC-MS identity, HPLC or UPLC purity, and quantitative net content.

For a blend, demand evidence that distinguishes and quantifies both components. One generic purity peak does not prove two identities or the claimed ratio.

Use /blog/how-to-read-peptide-coa-before-you-buy for the report workflow, /vendors to compare testing depth, and /methodology to understand how PeptidePub scores evidence. Only move to /go/bodybuilding-health after the exact product and lot meet your standard.

If vial concentration, BAC-water volume, or U-100 syringe-unit math enters the comparison, /tools/reconstitution-calculator makes the arithmetic visible. It is useful for comparing formats without turning a buyer guide into a personalized administration protocol.

Buyer Map: Which Option Fits Which Priority

Choose the prescription HGH lane when the goal is direct hormone replacement for confirmed growth hormone deficiency. That is a clinician-managed category and is not interchangeable with a research secretagogue purchase.

Choose CJC-1295 plus ipamorelin when the priority is complementary GHRH and ghrelin-receptor signaling, broad vendor availability, and a competitive market spanning blends and separate vials. Keep expected benefits tied to GH and IGF-1 signaling because long-term outcome trials of the stack are lacking.

Separate vials are the better fit when you want to audit each compound, choose DAC versus no-DAC explicitly, or avoid a fixed blend ratio. A blend is attractive when simplicity and a low combined price matter more and the vendor proves both component amounts.

Choose tesamorelin when the buying decision prioritizes the strongest specific human visceral-fat evidence in this peptide group. Keep the approximately 18% result in context: it came from adults with HIV-associated abdominal fat accumulation, not a general weight-loss trial.

For a focused CJC-1295 and ipamorelin purchase workflow, see /blog/cjc-1295-ipamorelin-buyer-guide and /blog/ipamorelin-dosage-price-buyer-guide.

Whatever lane wins, the checkout sequence should remain consistent:

1. Confirm the exact molecule and form.
2. Match the evidence to the intended goal.
3. Compare the effective after-code price.
4. Verify lot-matched identity, purity, and net content.
5. Account for shipping before ranking the deal.

This prevents a familiar growth-hormone label from collapsing three different mechanisms and evidence packages into one purchase decision.

FAQ

Is CJC-1295 plus ipamorelin the same as HGH?

No. HGH supplies recombinant growth hormone directly. CJC-1295 and ipamorelin stimulate endogenous GH through the GHRH and ghrelin receptors.

Which option has the best human evidence?

Prescription somatropin has established replacement evidence for confirmed growth hormone deficiency. Among the compared peptides, tesamorelin has the strongest specific clinical outcome data. CJC-1295 and ipamorelin evidence is mainly short-term GH and IGF-1 signaling.

Is tesamorelin better than CJC-1295 plus ipamorelin for belly fat?

Tesamorelin has approximately 18% visceral-fat reduction data in HIV-associated central fat accumulation, with pooled phase 3 summaries around 15% to 18% at 26 weeks. There is no head-to-head trial and no basis for promising the same result in the general population.

Is a CJC-1295 plus ipamorelin blend cheaper than separate vials?

It can be. In the current snapshot, Ascension's discounted 20 mg blend is $2.95 per combined mg. Compare exact component amounts and separate-vial totals because combined mg does not prove a 1:1 ratio or both identities.

What should a buyer verify before checkout?

Confirm the exact molecule and form, CJC DAC versus no-DAC, component amounts, lot-matched identity and purity, quantitative net content, named lab, report date, verifiable ID, delivered price after code and shipping, and whether the COA covers the exact product.

Bottom Line: Buy the Right Mechanism, Then Compare Price and Proof

HGH is direct replacement. CJC-1295 plus ipamorelin is a two-pathway secretagogue strategy. Tesamorelin has the clearest visceral-fat outcome evidence in its studied HIV population.

Current after-code checkpoints are $2.95 per combined mg for Ascension's blend, $3.96/mg for AMP ipamorelin, about $4.00 to $4.41/mg for CJC-1295, and about $4.78 to $5.00/mg for tesamorelin.

Price alone cannot select the compound. Match mechanism and evidence to the goal, then compare effective cost, delivered price, and lot proof.

Learn at /peptides/cjc-1295, /peptides/ipamorelin, and /peptides/tesamorelin. Check /prices for the live market and /vendors for testing transparency. Confirm the exact form, especially CJC-1295 DAC versus no-DAC, and demand blend-specific quantification.

The best purchase fits the priority, carries a competitive effective price, and has exact-lot proof of identity, purity, and quantity.